Colchicine attenuates kidney injury by modulating the NLRP3 inflammasome pathway

Gyuri Kim, Ga Young Heo, Bo Young Nam, YooJin Cho, Je Wook Yu, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han · 2026

Read Colchicine attenuates kidney injury by modulating the NLRP3 inflammasome pathway by Gyuri Kim, Ga Young Heo, Bo Young Nam, YooJin Cho, Je Wook Yu, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13449497.txt.

Description

Gyuri Kim and coauthors tested colchicine, a long-used anti-inflammatory drug, as a kidney protector in 2026. Chronic kidney disease involves ongoing inflammation, and one driver is the NLRP3 inflammasome, a protein complex that switches on inflammatory signals. Whether colchicine could calm that pathway in the kidney was still unclear.

Mice fed an adenine diet developed kidney disease, then received colchicine or saline daily for four weeks. Kidney tissue was sequenced for gene signals, and lab-grown kidney and immune cells were tested under stress with and without the drug. Treated animals showed lower levels of inflammatory markers. The work points to a cheap, familiar drug as a candidate for slowing kidney inflammation, pending human trials.

Catalog record

CREATORGyuri Kim, Ga Young Heo, Bo Young Nam, YooJin Cho, Je Wook Yu, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13449497

Browse the full library · About the Tower of Babel